CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions
Drug Resistant Epilepsy
Interventions
DRUG

Placebo

Placebo arm: participants will receive Placebo MPL-012 oil only through the trial participation. MPL-012 is produced by MediPharm Labs, each mL contains 0mg CBD and 0mg THC.

DRUG

CBD Isolate

CBD Isolate: MPL-015 is a CBD isolate, produced by MediPharm Labs, each mL contains 100mg CBD and 0mg THC.

DRUG

CBD CHE

CBD-CHE arm: MPL -016 is a CBD-enriched cannabis herbal extract, produced by MediPharm Labs, each mL contains 100mg of CBD and 3mg of THC.

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Research Manitoba

OTHER

lead

University of Manitoba

OTHER